Welcome to our book review site go-pdf.online!

You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.

Sign up

NK Cell Subsets in Health and Disease: New Developments
  • Language: en
  • Pages: 245

NK Cell Subsets in Health and Disease: New Developments

Natural Killer (NK) cells were discovered ca 1975, as the first group of lymphoid cells that were neither T cells nor B cells. Since then, the dissection of the biology of NK cells has been growing exponentially with many seminal discoveries from the identification of MHC class I-specific inhibitory receptors to the discovery of receptor-ligand pairs involved in NK cell activation and to the manipulation of NK cells in cancer. In this research topic, we asked a group of thought leaders in NK cell biology to review recent advances in their origins and biology, and their roles in cancer, infection and inflammation. Together, these 25 articles provide a timely survey of NK cells as critical immunologic components of health and disease. They will hopefully prompt further dialogue and developments in basic and translational immunology.

Novel Immunological Biomarkers for Allogeneic HSCT Outcome
  • Language: en
  • Pages: 259
Tale of Rouen
  • Language: en
  • Pages: 317

Tale of Rouen

It is said "those who [do not] remember the past are [doomed] to repeat it." - George Santayana But sometimes necessary secrets trap one in an endless cycle of tragedy. Jillian, a divorced researcher, travels to Urbino, Italy, to get away from life in the United States. While she explores the winding cobblestone streets of the mountaintop town, she encounters a man from the Renaissance. Initially, she thinks he is a costumed tour guide, then she learns he is a ghost with a strange story. Rouen is cursed to wander within the boundaries of Urbino for a thousand years. Jillian is the first person in over a century to notice that he exists. Although it goes against his better judgement, he befri...

Real-World Data and Real-World Evidence in Hematologic Malignancies
  • Language: en
  • Pages: 196
Contact Dermatitis
  • Language: en
  • Pages: 164

Contact Dermatitis

This book centralizes on the subject of contact dermatitis. It aims to provide the dermatologist with a sound base of clinical wisdom and key scientific findings to make an accurate diagnosis and management plan. SPECIAL FEATURES: - Describes numerous possible allergens that cause contact dermatitis. - Provides details of research in the basic sciences to help our readers understand more about contact dermatitis. - Provides a comprehensive description of recently developed methods that have evolved for the diagnosis of contact dermatitis. - Provides a concise, clinically focused, user-friendly format, which can rapidly improve your knowledge of the disease. The past decade has seen significant changes in contact dermatitis. Our understanding of the pathophysiology, our diagnostic approaches, and management of the disease has evolved. In this volume, some of the world's most highly regarded experts discuss areas that have seen significant improvement, as well as areas for future development.

Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation
  • Language: en
  • Pages: 157
Emerging Therapeutics for Immune Tolerance
  • Language: en
  • Pages: 327

Emerging Therapeutics for Immune Tolerance

None

New Frontiers in Gene-Modified T Cell Technology
  • Language: en
  • Pages: 222

New Frontiers in Gene-Modified T Cell Technology

The development, clinical translation and recent efficacy of novel gene therapies targeting refractory malignancies has led to research that extends this technology to a variety of infectious and rheumatological diseases. Unlike conventional drugs or antibodies, T cells have the potential to target and exert effector function in response to disease in a dynamic manner, acting as a “living drug”. The most efficacious form of gene-modified T cells to date is the chimeric antigen receptor (CAR)-modified T cell, which redirects the specificity of T cells to an antigen expressed by tumor cells. Clinical experience with autologous CAR-T cells, primarily in hematologic malignancies, has underscored the feasibility and safety of the approach, while also demonstrating dramatic and sustained antitumor effects through mechanisms orthogonal to those of traditional anticancer therapies. However, several challenging obstacles must be surmounted in order to improve the broader efficacy of this approach.